FindTrial
Sign In

Diagnostic threshold analysis of serum GM test and bronchoalveolar lavage fluid GM test in critically ill patients with invasive pulmonary aspergillosis

Diagnostic threshold analysis of serum GM test and bronchoalveolar lavage fluid GM test in critically ill patients with invasive pulmonary aspergillosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058083
Enrollment
Unknown
Registered
2022-03-29
Start date
2022-03-28
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

invasive pulmonary aspergillosis

Interventions

Gold Standard:According to the classification diagnostic criteria of ''Diagnostic Criteria and Treatment Principles of Invasive Pulmonary Fungal Infections'' by the China Invasive Pulmonary Fungal Inf
Index test:Use PLATELIATM Aspergillus Antigen Detection Kit (reagent manufacturer: Bole, USA), product number 62794, and store the kit at 2-8 ?. The experimental principle is one-step immunoenzyme san

Sponsors

Shenzhen Longgang District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 93 Years

Inclusion criteria

Inclusion criteria: From January 2018 to September 2021, the critical ill patients of serum GM test and BALF GM test were examined by the Department of Intensive Care Medicine of our hospital.

Exclusion criteria

Exclusion criteria: 1. Antifungal drugs have been used before specimen collection; 2. Factors influencing galactomannan test results: incomplete clinical data.

Design outcomes

Primary

MeasureTime frame
galactomannan antigen test;—

Countries

China

Contacts

Public ContactShe Xiaolong

Shenzhen Longgang District People's Hospital

sxlong09@126.com+86 18823846983

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026